Viroclinics-DDL rebrands to Cerba Research

Viroclinics-DDL (referred to herein as Cerba Research, the Netherlands) a world leading vaccine and antiviral specialty laboratory providing research and clinical trial solutions rooted in virology, proudly announces changing its name to Cerba Research as of the 1st of April 2024.

Prioritising Lung Health: How FeNO can help to tackle Lung Conditions, the UK’s 3rd Largest Threat

A new report from PwC commissioned by Asthma+Lung UK has highlighted the alarming crisis surrounding Lung Health in the UK.

October 4, 2023

Outbreak of piercing infections in Australia traced to contaminated aftercare solution

Researchers in New South Wales, Australia, used genomic sequencing to trace an outbreak of Pseudomonas aeruginosa infections following ear piercings to a specific batch of

September 4, 2023

High Tide Q2 Revenue Flat to Q1 at C$118.1 Million

High Tide Reports Third Consecutive Quarter of Record Revenue and Adjusted EBITDA of $118.1 Million and $6.6 Million, Respectively The Company Achieved Significant Sequential Improvement

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.